Novo Nordisk's Amycretin Shows Promise in Early Trials

Novo Nordisk's experimental weight-loss pill, amycretin, demonstrated safety and tolerability in early-stage trials. The pill showed significant weight reduction, with patients losing up to 13.1% of their weight in 12 weeks. Full data from the study will be presented at the European Association for the Study of Diabetes meeting.

Novo Nordisk's experimental weight-loss pill amycretin, reported to be safe and tolerable according to early-stage trials, exhibited only mild-to-moderate side effects. These trials showed a significant weight loss among participants, leading to a surge in the company's shares.

In March, data revealed that amycretin helped participants lose up to 13.1% of their weight over 12 weeks. This finding compares favorably to previous results from the company's blockbuster drugs Wegovy and Ozempic.

As Novo prepares to present the full Phase I trial data at the European Association for the Study of Diabetes meeting, anticipation builds. Amycretin targets gut and pancreas hormones affecting hunger and was tested on overweight or obese patients. The results suggest further clinical development.

(With inputs from agencies.)